JPRN-jRCT2080225262已完成2 期
ONO-4538 Phase II Study A Multicenter, Open-label, Uncontrolled Study in non-small cell lung cancer and gastric cancer (ONO-4538-88/TASUKI-88)
ONO PHARMACEUTICAL CO., LTD.0 个研究点目标入组 60 人开始时间: 2020年7月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients with driver mutation/translocation-negative, refractory to radical radiation, and stage IIIB/IIIC/IV or recurrent non-small cell lung cancer and patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).
- •2.ECOG Performance Status of 0-1
- •3.Patients with life expectancy of at least 90 days
排除标准
- •1. Patients with multiple cancers
- •2. Complication or history of severe hypersensitivity reactions to antibodies and any other drugs
研究者
相似试验
已完成
2 期
ONO-4538 Phase II Study (ONO-4538-91/TASUKI-91)Patients with unresectable or recurrent biliary tract cancer (including intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, and duodenal papilla cancer) that is refractory or intolerant to gemcitabine-based and S-1-based regimens with CPS >=1.JPRN-jRCT2080225006ONO PHARMACEUTICAL CO., LTD.80
未知
2 期
ONO-2745 Phase II StudyPostoperative patients requiring sedation during artificial ventilation in intensive care unit.JPRN-jRCT2080221927ONO PHARMACEUTICAL CO.,LTD.90
未知
2 期
ONO-4053 Phase 2a studyseasonal allergic rhinitis (Japanese cedar pollinosis)JPRN-jRCT2080222655ONO PHARMACEUTICAL CO.,LTD.200
未知
2 期
ONO-2745 IIb/III StudyPatients undergoing surgery requiring general anesthesiaJPRN-jRCT2080221928ONO PHARMACEUTICAL CO.,LTD.325
进行中（未招募）
不适用
An open-label, multi-center, Phase I-Ib/II study of AUY922 administered as single agent and in combination with bortezomib with or without dexamethasone in adult patients with relapsed or refractory multiple myelomaEUCTR2007-006279-35-DEovartis Pharma Services AG74